1
|
Cao F, Kang XH, Wang DF, Ma L, Cao XJ, Wang Y, Gao YY, Miao ZH, Deng HB, Gong YB. [Mechanism of lncRNA-SRLR induced invasion and metastasis in U2OS osteosarcoma cells]. Zhonghua Zhong Liu Za Zhi 2020; 42:1007-1013. [PMID: 33342156 DOI: 10.3760/cma.j.cn112152-20190404-00216] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
Abstract
Objective: To explore the potential mechanism of sorafenib resistance associated long non-coding RNA (lncRNA-SRLR) promoted invasion and metastasis in U2OS osteosarcoma cells. Methods: We transfected U2OS cells with negative control lentivirus (LV-NC) or lncRNA-SRLR overexpressed lentivirus (LV-over/SRLR) particles. LV-NC and LV-over/SRLR stable transfected cells (U20S/NC and U20S/SRLR) were selected by primary cell culture medium containing puromycin. The mRNA expressions of lncRNA-SRLR and procollagen-lysine, procollagen-lysine 2-oxoglutarate 5-dioxygenase 2 (PLOD2) were detected by quantitative real-time polymerase chain reaction (qRT-PCR). The effect of lncRNA-SRLR on the invasion of U2OS cells were determined by wound-healing assay and Transwell migration assay. The effect of SRLR on the interleukin-6 (IL-6) secretion of U2OS cells was evaluated by enzyme-linked immunosorbent assay (ELISA) analysis. The subcellular distribution of SRLR in U2OS cells was detected by fluorescence in situ hybridization (FISH) analysis.The expression of PLOD2 in cells was detected by immunofluorescence (IF). The expressions of PLOD2 and focal adhesion kinase (FAK)/signal transducer and activator of transcription 3 (STAT3) signal pathway related proteins in U2OS/NC and U2OS/SRLR cells were detected by western blotting. Results: qRT-PCR assay showed that mRNA expressions of lncRNA-SRLR and PLOD2 in U2OS/SRLR cells were (3 964.97±0.05) and (2.77±0.11), respectively, significantly higher than those in U2OS/NC cells (P<0.001 or P<0.01). The results of wound-healing and Transwell migration assay showed that over-expression of SRLR markedly promoted the invasion ability of U2OS cells (P<0.05). The result of ELISA analysis showed that the IL-6 secretions in U2OS/NC or U2OS/SRLR cells were (125.38±11.22) pg/ml or (119.97±13.43) pg/ml, without statistical significance (P>0.05). The subcellular distribution assay revealed that lncRNA-SRLR is predominately located in the nucleus. The result of IF showed that compared with U2OS/NC cells, the expression of PLOD2 was up-regulated in U2OS/SRLR cells. The result of western blotting showed that over-expression of SRLR significantly increased the expression levels of PLOD2, phosphorylation (p)-FAK and p-STAT3 in U2OS cells (P<0.01). Conclusion: lncRNA-SRLR promotes invasion and metastasis of osteosarcoma by activating PLOD2-FAK/STAT3 signal axis.
Collapse
Affiliation(s)
- F Cao
- Department of Orthopaedics, Pingdingshan First People's Hospital, Pingdingshan 467000, China
| | - X H Kang
- Department of Oncology, the First Affiliated Hospital of Xinxiang Medical University, Weihui 453100, China
| | - D F Wang
- Department of Orthopaedics, Pingdingshan First People's Hospital, Pingdingshan 467000, China
| | - L Ma
- Department of Orthopaedics, Pingdingshan First People's Hospital, Pingdingshan 467000, China
| | - X J Cao
- Department of Orthopaedics, Pingdingshan First People's Hospital, Pingdingshan 467000, China
| | - Y Wang
- Department of Oncology, the First Affiliated Hospital of Xinxiang Medical University, Weihui 453100, China
| | - Y Y Gao
- Department of Oncology, the First Affiliated Hospital of Xinxiang Medical University, Weihui 453100, China
| | - Z H Miao
- Department of Oncology, the First Affiliated Hospital of Xinxiang Medical University, Weihui 453100, China
| | - H B Deng
- Department of Oncology, Longhua Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai 200032, China
| | - Y B Gong
- Department of Oncology, Yueyang Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai 200437, China
| |
Collapse
|
2
|
Kang XH, Wang K, Wang Y, Zhao HK, Zhang J, Zhao KL, Miao ZH, Xu ZY, Cao F, Gong YB. [Mechanism of PLOD2 induced osimertinib resistance in non-small cell lung cancer HCC827 cells]. Zhonghua Zhong Liu Za Zhi 2020; 42:210-215. [PMID: 32252199 DOI: 10.3760/cma.j.cn112152-20190322-00186] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
Abstract
Objective: To investigate the effects of osimertinib on proliferation, migration and invasion of procollagen-lysine 2-oxoglutarate 5-dioxygenase 2 (PLOD2) overexpressing HCC827 cells and explore the potential mechanism of PLOD2 induced osimertinib resistance. Methods: We transfected HCC827 cells with LV-vector and LV-over/PLOD2. The expression of PLOD2 was detected by quantitative real time polymerase chain reaction (qRT-PCR) and western blotting. The effects of osimertinib on the proliferation of HCC827-vector and HCC827-PLOD2 cells were evaluated by 3-(4, 5-dimethyl-2-thiazolyl)-2, 5-diphenyl-2H tetrazolium bromide (MTT) assay. The effects of osimertinib on the migration and invasion of HCC827-vector and HCC827-PLOD2 cells were determined by Transwell assays. The expressions of E-cadherin and vimentin in cells were detected by immunofluorescence (IF). The expressions of epithelial-mesenchymal transition (EMT), FAK-PI3K/AKT and MAPK signal pathway related proteins were detected by western blotting. Results: The MTT assay showed that HCC827-PLOD2 cells were hyposensitive to osimertinib. The 50% inhibitory concentration (IC(50)) and resistance index of osimertinib for HCC827-PLOD2 cells was over 1 000 nmol/L and over 100, respectively. The result of wound healing assay showed that the migration distance of HCC827-PLOD2 was about (2.13±0.21) fold changes as that of HCC827-vector cells. The result of Transwell assay showed that the numbers of HCC827-PLOD2 passing through the matrix membrane were (212.78±10.43), significantly higher than (101.32±12.52) of HCC827-vector cells (P<0.01). The result of IF showed that compared with HCC827-vector cells, the expression of E-cadherin was down-regulated while vimentin was up-regulated in HCC827-PLOD2 cells. Osimertinb downregulated E-cadherin and upregulated vimentin expression in HCC827-vector cells but had limited effect in HCC827-PLOD2 cells. The result of western blotting showed that PLOD2 significantly increased vimentin expression level while decreased E-cadherin expression level. Osimertinib inhibited the expression of p-EGFR, but did not affect the expressions of PLOD2, p-FAK, p-AKT, p-ERK, vimentin and E-cadherin in HCC827-PLOD2 cells. Conclusion: PLOD2 confers resistance to osimertinib in HCC827 cells by regulating EMT, FAK-PI3K/AKT and MAPK signal pathways.
Collapse
Affiliation(s)
- X H Kang
- Department of Oncology, the first Affiliated Hospital of Xinxiang Medical University, Xinxiang 453100, China
| | - K Wang
- Department of Oncology, the first Affiliated Hospital of Xinxiang Medical University, Xinxiang 453100, China
| | - Y Wang
- Department of Oncology, the first Affiliated Hospital of Xinxiang Medical University, Xinxiang 453100, China
| | - H K Zhao
- Department of Oncology, the first Affiliated Hospital of Xinxiang Medical University, Xinxiang 453100, China
| | - J Zhang
- Department of Oncology, the first Affiliated Hospital of Xinxiang Medical University, Xinxiang 453100, China
| | - K L Zhao
- Department of Oncology, the first Affiliated Hospital of Xinxiang Medical University, Xinxiang 453100, China
| | - Z H Miao
- Department of Oncology, the first Affiliated Hospital of Xinxiang Medical University, Xinxiang 453100, China
| | - Z Y Xu
- Department of Oncology, Longhua Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai 200032, China
| | - F Cao
- Department of Oncology, the first Affiliated Hospital of Xinxiang Medical University, Xinxiang 453100, China
| | - Y B Gong
- Department of Oncology, Yueyang Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai 200437, China
| |
Collapse
|